Cytosar-U, Cytarabine Newswire

Cytosar-U, Cytarabine Newswire

Comprehensive Real-Time News Feed for Cytosar-U, Cytarabine (generic).

Results 1 - 20 of 60 in Cytosar-U, Cytarabine (generic)

  1. GlycoMimetics Announces High Overall Response Rates, Low Induction...Read the original story

    Wednesday May 17 | BioSpace

    GlycoMimetics, Inc. today announced the release of abstracts containing new data from the ongoing Phase 2 clinical trial of its product candidate GMI-1271, an E-selectin antagonist, in patients with acute myeloid leukemia . The data will be presented at the June annual meetings of the American Society of Clinical Oncology and the European Hematology Association .

    Comment?

  2. GlycoMimetics Announces High Overall Response Rates, Low Induction...Read the original story

    Thursday May 18 | Customer Interaction Solutions

    GlycoMimetics Announces High Overall Response Rates, Low Induction Mortality, Promising Initial Survival Outcomes, and Supportive Biomarker Data from Phase 1/2 Trial of GMI-1271 in AML GlycoMimetics, Inc. today announced the release of abstracts containing new data from the ongoing Phase 2 clinical trial of its product candidate GMI-1271, an E-selectin antagonist, in patients with acute myeloid leukemia . The data will be presented at the June annual meetings of the American Society of Clinical Oncology and the European Hematology Association .

    Comment?

  3. Specialist to explain cancer drug damageRead the original story w/Photo

    Thursday May 11 | NEWS.com.au

    A CANCER drug specialist from Sydney may for the first time shed light on how much damage was done to the ten underdosed chemotherapy victims who were given half the recommended daily dose. In a directions hearing the Deputy State Coroner, Anthony Schapel, said a Sydney University professor of pharmacy, Professor Alan Boddy - a pharmacogeneticist - would be called to give evidence on "causality".

    Comment?

  4. Staff involved in RAH chemotherapy mistakes stood downRead the original story w/Photo

    Wednesday May 10 | ABC News

    Two staff involved in the under-dosing of a chemotherapy drug at the Royal Adelaide Hospital have been stood down, South Australia's Health Minister Jack Snelling has confirmed. Previously the ABC has reported that the dosage error led to an independent review which found that a series of significant clinical governance failures at Royal Adelaide Hospital haematology unit.

    Comment?

  5. RYDAPT (midostaurin) Approved for the Treatment of FLT3-Mutated Acute ...Read the original story

    Wednesday May 3 | PressReleasePoint

    Biologics, Inc. , a McKesson Specialty Health oncology pharmacy services company, announced today it has been selected by Novartis to be in the distribution network for RYDAPTA , a new oral treatment for adults with newly-diagnosed acute myeloid leukemia who are FLT3 mutation-positive. The AML treatment strategy has remained virtually unchanged for more than 25 years,1 so the development of RYDAPT is a welcomed advancement in cancer care and gives providers another treatment option for this challenging disease.

    Comment?

  6. RYDAPT (Midostaurin) Approved For The Treatment Of FLT3-Mutated Acute ...Read the original story

    Tuesday May 2 | BioSpace

    Biologics, Inc. , a McKesson Specialty Health oncology pharmacy services company, announced today it has been selected by Novartis to be in the distribution network for RYDAPTA , a new oral treatment for adults with newly-diagnosed acute myeloid leukemia who are FLT3 mutation-positive. The AML treatment strategy has remained virtually unchanged for more than 25 years,1 so the development of RYDAPT is a welcomed advancement in cancer care and gives providers another treatment option for this challenging disease.

    Comment?

  7. SAMHD1 protects cancer cells from various nucleoside-based antimetabolitesRead the original story

    Tuesday May 2 | CiteULike

    To insert individual citation into a bibliography in a word-processor, select your preferred citation style below and drag-and-drop it into the document. AbstractRecently, we demonstrated that sterile alpha motif and HD domain containing protein 1 is a major barrier in acute myelogenous leukemic cells to the cytotoxicity of cytarabine , the most important drug in AML treatment.

    Comment?

  8. FDA approves 1st targeted drug for certain leukemia patientsRead the original story w/Photo

    Friday Apr 28 | The Oak Ridge Observer

    Midostaurin was approved by the FDA for the treatment of adults with newly diagnosed acute myeloid leukemia , who are FLT3 mutation-positive in combination with cytarabine and daunorubicin induction and cytarabine consolidation. The FDA has approved midostaurin for the treatment of adult patients with newly diagnosed acute myeloid leukemia , in combination with chemotherapy.

    Comment?

  9. Outcome after intensive reinduction therapy and allogeneic stem cell...Read the original story

    Apr 27, 2017 | CiteULike

    To insert individual citation into a bibliography in a word-processor, select your preferred citation style below and drag-and-drop it into the document. Given that 30-40% of children with acute myeloid leukaemia relapse after primary therapy it is important to define prognostic factors and identify optimal therapy.

    Comment?

  10. New drug compounds could provide non-toxic, effective way to inhibit enzymes that cause cancersRead the original story w/Photo

    Apr 25, 2017 | PhysOrg Weblog

    Drug compounds being developed at Purdue University could effectively target and inhibit protein kinase enzymes and secondary mutated versions that drive multiple types of cancers. The compounds are non-toxic compared to conventional drugs, potentially eliminating adverse patient side effects.

    Comment?

  11. What's Next For Jazz Pharmaceuticals?Read the original story w/Photo

    Apr 10, 2017 | Seeking Alpha

    Coming hot off its latest acquisitions, Jazz Pharmaceuticals seems poised to make an impact on the treatment of acute myeloid leukemia, with a decision from the FDA likely to come in 2017. Should this kick off your radar? AML is an aggressive, highly difficult-to-treat form of leukemia, which is currently managed with high-dose chemotherapy and stem cell transplantation, if the patient can handle it.

    Comment?

  12. Jazz Pharmaceuticals Completes Rolling Submission of New Drug...Read the original story w/Photo

    Apr 2, 2017 | Drugs.com

    Jazz Pharmaceuticals plc today announced the completion on March 31, 2017 of a rolling submission of a New Drug Application to the U.S. Food and Drug Administration for the approval of Vyxeosa liposome for injection, an investigational treatment for acute myeloid leukemia , a rapidly progressing and life-threatening blood cancer. 1 The company has requested a priority review for the Vyxeos NDA, which, if granted, would accelerate the expected timing of the FDA's review.

    Comment?

  13. Jazz Pharma Completes Rolling Submission Of New Drug Application For...Read the original story

    Apr 2, 2017 | BioSpace

    Jazz Pharma Completes Rolling Submission Of New Drug Application For Vyxeos , An Investigational Treatment For Acute Myeloid Leukemia of a rolling submission of a New Drug Application to the U.S. Food and Drug Administration for the approval of Vyxeos liposome for injection, an investigational treatment for acute myeloid leukemia , a rapidly progressing and life-threatening blood cancer. 1 The company has requested a priority review for the Vyxeos NDA, which, if granted, would accelerate the expected timing of the FDA's review.

    Comment?

  14. Mateon Therapeutics Reviews 2016 Highlights and Reports 2016 Financial ResultsRead the original story

    Mar 30, 2017 | Customer Interaction Solutions

    Mateon Therapeutics, Inc. , a biopharmaceutical company developing vascular disrupting agents for the treatment of orphan oncology indications, today provided a corporate update and announced 2016 financial results.

    Comment?

  15. Jazz Pharma And Nippon Shinyaku Co., Ltd. Enter Into License...Read the original story

    Mar 29, 2017 | BioSpace

    Jazz Pharma And Nippon Shinyaku Co., Ltd. Enter Into License Agreements For The Development And Commercialization Of Defitelio And Vyxeos In Japan /PRNewswire/ -- Jazz Pharmaceuticals plc today announced that it has entered into license agreements with Nippon Shinyaku, Co., Ltd. for DefitelioA and Vyxeos , or CPX-351, in Under the terms of the agreements, Nippon Shinyaku will receive exclusive rights to develop and commercialize Defitelio and Vyxeos in in return for an upfront payment to Jazz Pharmaceuticals and subsequent payments based on the successful achievement of certain regulatory and commercial milestones.

    Comment?

  16. The life-saving treatment thata s being thrown in the trashRead the original story w/Photo

    Mar 29, 2017 | WWLP

    South Korea's former president has arrived at a court for hearing on a prosecutors' request for her arrest for cor In early August 2015, Chris Lihosit fell ill with an exhausting, dehydrating and pyjama-soaking fever that mysteriously disappeared two days later. Then the same thing happened again, and it settled into a disturbing pattern: midweek chills and an escalating fever that would break on Sunday.

    Comment?

  17. New Drugs from Marine Organisms in Alzheimer's DiseaseRead the original story

    Mar 29, 2017 | CiteULike

    Alzheimer's disease is a multifactorial neurodegenerative disorder. Current approved drugs may only ameliorate symptoms in a restricted number of patients and for a restricted period of time.

    Comment?

  18. Mateon Therapeutics Announces Initial Data from Third Cohort of Phase ...Read the original story

    Mar 15, 2017 | World News Report

    SOUTH SAN FRANCISCO, Calif., March 15, 2017 -- Mateon Therapeutics, Inc. , a biopharmaceutical company developing vascular disrupting agents for the treatment of orphan oncology indications, today announced preliminary data from the third dose cohort of the ongoing Phase 1b study OX1222 in patients with relapsed/refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome . OX1222 is a dose-ranging Phase 1b study of OXi4503 combined with cytarabine.

    Comment?

  19. Mateon Therapeutics Announces Initial Data from Third Cohort of Phase ...Read the original story

    Mar 15, 2017 | Customer Interaction Solutions

    Mateon Therapeutics, Inc. , a biopharmaceutical company developing vascular disrupting agents for the treatment of orphan oncology indications, today announced preliminary data from the third dose cohort of the ongoing Phase 1b study OX1222 in patients with relapsed/refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome . OX1222 is a dose-ranging Phase 1b study of OXi4503 combined with cytarabine.

    Comment?

  20. Cellectis Reports 4th Quarter and Full Year 2016 Financial ResultsRead the original story

    Mar 6, 2017 | Customer Interaction Solutions

    Cellectis S.A. , a biopharmaceutical company focused on developing immunotherapies based on gene edited CAR T-cells , today announced its results for the three-month period ended December 31, 2016 and for the year ended December 31, 2016. Cellectis will host an earnings call on March 7, 2017 at 8:00am Eastern Time to discuss its financial results and provide a general business update.

    Comment?